Pipeline Previews openaccess articles

October 2014 | Volume 13 | Issue 10 | Feature | 1293 | Copyright © 2014

Abstract

Pipeline Previews brings to you information on the newest drugs and medical products as they become available to the dermatologic community. This department may include additional information from the manufacturers, plus reports from physicians who wish to share their clinical experience with these new products. In addition, we will inform our readers about the latest drugs receiving Food and Drug Administration (FDA) approval.

Purchase Original Article

Purchase a single fully formatted PDF of the original manuscript as it was published in the JDD.

Download the original manuscript as it was published in the JDD.

Contact a member of the JDD Sales Team to request a quote or purchase bulk reprints, e-prints or international translation requests.

To get access to JDD's full-text articles and archives, upgrade here.

Save an unformatted copy of this article for on-screen viewing.

Print the full-text of article as it appears on the JDD site.

→ proceed | ↑ close

Inocutis introduces NEW breakthrough TREATMENT FOR COLD SORES

Sitavig® 50mg (Acyclovir) Muco-Adhesive Buccal Tablet

If you have never experienced a cold sore, consider yourself lucky! Millions of people get more than one episode per year and for up to two weeks that the sore may last, virtually everyone is “watching your lips!” And, not in a good way.

Now, there is a breakthrough treatment for cold sores with the potential to abort, shorten the duration, increase the amount of time between episodes. South Carolina-based, Innocutis, is pleased to announce the introduction of Sitavig® (ACYCLOVIR), 50mg Buccal Tablet. Sitavig represents a treatment breakthrough in the herpes labialis (HSV-1 cold sore) category, because of its unique vehicle and delivery system.

Sitavig uses a proprietary delivery technology called Luriad® which consists of a tablet that sticks to the gum above the incisor tooth on the side of the lip that is infected with a cold sore. 8mm in diameter and 2.2 – 2.6 mm in thickness, this white-toslightly- yellow tablet is tasteless and odorless. It dissolves to provide a sustained release of medicine. It is available by prescription only at local retail pharmacies.

Phase III Study Proves it Works!

A Phase III, randomized, double-blind, placebo controlled study1, including 775 subjects demonstrated that a single low dose of Sitavig acyclovir buccal tablet improved all clinical parameters of labial herpes when applied shortly after symptoms occurred. Most notable, Sitavig decreased duration of episode, increased the percentages of blocked lesions and delayed by 105 days the recurrence of the next herpes episodes.2 It is well known that the standard of care, systemic antiviral drugs, is typically prescribed at high doses in the treatment of labial herpes (HL). However, Sitavig's innovative drug delivery system that provides a high sustained-release local exposure of acyclovir in the oral mucosa, supporting its evaluation as single low dose in HL.

“We are very excited to bring Sitavig to the North American markets,” said Charles Jenkins, Vice President of Marketing for Innocutis. “Up to ninety percent of Americans have been exposed to HSV-1 by the time they are 50, but there hasn't been a real breakthrough product to address this problem in many years. Sitavig is revolutionary because unlike systemic drugs and topical prescription creams, Sitavig requires application to the gum only once-per-episode.”

If there is anything good to be said about cold sores it is that they often come with a warning; a tingling or burning sensation before anything is visible on the lips. This “warning” stage is called prodrome and when Sitavig was applied within one hour after prodrome. It provided clinical benefit to cold sore sufferers, reducing the occurrence of vesicular lesions, primary or non-primary, which is the most important burden of the disease. It also prevented and delayed the recurrence of the next herpes episode, making Sitavig an attractive alternative option to systemic antiviral treatment for individuals with recurrent cold sores when applied within one hour after the onset of prodromal symptoms.

The Promius Promise Physician Portal

To help physicians who would like to better be able to follow a patient's progress while taking Promius Pharma's generic isotretinoin, Zenatane™(isotretinoin capsules USP) AB rated to Accutane, the company has created a web-based provider portal. It was designed to allow any authorized prescriber using the Promius Promise, to obtain easy, instant access to secure patient data related to their prescriptions handled by the Promius Promise.

The HIPAA secured web portal includes a list of all patients who are enrolled in the Promius Promise program (when processed through Direct Success Pharmacy), patient demographics, dates of prescriptions received and prescription shipments, information on pending prescriptions, reports showing communication with the patients and HCP office to allow the patient to receive isotretinoin within the iPledge® Do Not Dispense window, and a messaging tool allowing HCP office to send questions and receive responses within the portal itself or on their smart phone devices as preferred.

Aqua Pharmaceuticals, LLC Announces FDA Approval of ACTICLATE™ Tablets

Aqua Pharmaceuticals, an Almirall company, announced ACTICLATE ™, a tetracycline-class antibacterial indicated for the treatment of a number of infections, including adjunctive therapy in severe acne, is FDA-approved as 150 mg and 75 mg tablets.

ACTICLATE™ 150 mg tablets have two functional scores, providing several dosing options to physicians and patients. The ACTICLATE™ film-coated, round 75 mg tablets and ovalshaped, dual-scored 150 mg tablets are designed to be small and easy to swallow. Utilization of the latest manufacturing technology has allowed 150 mg of doxycycline to be formulated in a substantially reduced tablet size for ACTICLATE™.

↑ back to top


  • 1
  • 2

Related Articles